Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression
| Status: | Completed |
|---|---|
| Conditions: | Chronic Pain, Chronic Pain, Depression, Major Depression Disorder (MDD), Endocrine |
| Therapuetic Areas: | Endocrinology, Musculoskeletal, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2013 |
| Start Date: | November 2011 |
| End Date: | January 2013 |
| Contact: | Jim D Doorley, BA |
| Email: | jdoorley@partners.org |
| Phone: | 617-724-3222 |
The primary aim of this study is to test the feasibility and efficacy of Mindfulness Based
Cognitive Therapy (MBCT) training for the treatment of depressive symptoms in patients with
chronic pain. The study also aims to elucidate the mechanisms underlying MBCT on a
psychological and neurobiological level. For this purpose the study subjects will fill out
several psychological questionnaires related to mindfulness, depression and chronic pain.
Moreover this study involves optional fMRI scans of the brain and blood measures before and
after the intervention.
Main hypotheses:
1. The MBCT training will be a feasible intervention in patients with chronic pain and
co-morbid depression as defined by no occurrence of serious adverse events related to
the intervention and a retention rate of more than 70% in the subjects assigned to the
MBCT arm.
2. Patients who have completed the MBCT training will demonstrate a significant decrease
in depressive symptoms as measured on the Quick Inventory of Depressive Symptomatology
- Clinician rated (QIDS-C16), and the Hamilton Rating Scale for Depression (HRSD17)
(QIDS-C/HRDS) severity scale for depressive symptoms (the primary outcome measure),
compared to the control group.
Inclusion Criteria:
- The presence of Chronic Pain, which has persisted for at least 3 months.
- Meets criteria of Major Depressive Disorder, Dysthymic Disorder or Depressive
disorder NOS as defined by DSM-IV criteria.
- Have a minimum score of depressive symptoms of > 10 as rated on the QIDS-C,
administered during the screen.
- Able to provide written informed consent.
- Adults 18 years or older
- English-language literacy.
Exclusion Criteria:
- Serious suicide or homicide risk, as assessed by evaluating clinician.
- Severe and unstable medical illness including cardiovascular, hepatic, renal,
respiratory, endocrine, neurological or hematological disease for which
hospitalization is likely to be required within the next half year.
- The following DSM-IV disorders: any bipolar disorder (current or past), current
psychotic symptoms, or a primary psychotic disorder (current or past). Entry of
patients with anxiety disorder will be permitted if the depressive disorder is judged
to be the predominant disorder, in order to increase accrual of a clinically relevant
sample.
- Active diagnosis of substance abuse or dependence disorders within the last 3 months.
We found this trial at
1
site
Click here to add this to my saved trials
